Zaleplon: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Zaleplon. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Headache | 42% |
| Dizziness | 9% |
| Nausea | 8% |
| Asthenia | 7% |
| Abdominal pain | 6% |
| Somnolence | 6% |
| Amnesia | 4% |
| Eye pain | 4% |
| Dysmenorrhea | 4% |
| Paresthesia | 3% |
| Malaise | 2% |
| Anorexia | 2% |
| Depersonalization | 2% |
| Hypesthesia | 2% |
| Tremor | 2% |
| Abnormal vision | 2% |
| Hyperacusis | 2% |
| Parosmia | 2% |
| Photosensitivity reaction | 1% |
| Colitis | 1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Sonata is indicated for the short-term treatment of insomnia. Sonata has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see Clinical Trials under CLINICAL PHARMACOLOGY ). It has not been shown to increase total sleep time or decrease the number of awakenings. The clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. The final formal assessments of sleep latency were performed at the end of treatment.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.